On the 2nd, the pharmaceutical company Alvogen Korea announced that Lee Wook-se had been appointed as the new CEO.
The new CEO Lee Wook-se has held key positions at leading domestic and international pharmaceutical companies, including Chong Kun Dang, Novartis, and Merck Serono, gaining extensive experience in pharmaceutical sales and overall organizational operations. Alvogen described him as "a leader with an on-site management philosophy and a global sense."
Lee Wook-se noted, "Alvogen Korea will fulfill its social responsibility as a global healthcare corporation contributing to the improvement of human health," and stated, "I will lead the company's sustainable growth by integrating the field experience, sales philosophy, and transparent ethical management I have accumulated over the years."
Alvogen Korea is the Korean branch of the multinational company Lotus Group, headquartered in Taiwan. It has a diverse portfolio of over 200 products across various areas, including obesity treatments, central nervous system (CNS) drugs, nephrology, and cardiovascular medications, as well as over-the-counter drugs.